Nasdaq · CIK 0001553643
RLMD RELMADA THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing 32 d ago. Close $3.39 on Oct 9, 2026, +76% from the 52-week low and -57% from the high.
RELMADA THERAPEUTICS, INC. (RLMD) has 26 SEC Form 4 filings on file from 7 insiders, the latest filed on Sep 11, 2026. In the last 90 days insiders made 2 open-market buys worth $1.7M and 0 open-market sells worth $0, net +$1.7M.
13 open-market trades have been scored at RLMD. The newest: Sergio Traversa (Chief Executive Officer) bought $828k of stock on Sep 9, 2026, filed Sep 11, 2026, scored 59 (moderate). The largest of the 13 shown: Maged Shenouda (Chief Financial Officer) bought $1.1M on Nov 5, 2025, scored 76 (notable). 2 insiders bought within 14 days of each other around Sep 9, 2026.
RLMD closed at $3.39 on Oct 9, 2026, 76% above its 52-week low and 57% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at RELMADA THERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 59Moderate | Sergio Traversa Chief Executive Officer buy | $828k 200,000 shares | +15% | - | |
| 59Moderate | Maged Shenouda Chief Financial Officer buy | $844k 200,000 shares | +25% | - | |
| 42Moderate | Maged Shenouda Chief Financial Officer buy | $48k 11,665 shares | +1% | +1630% from low-3% from high | |
| 48Moderate | Sergio Traversa Chief Executive Officer buy | $113k 27,500 shares | +2% | +1630% from low-3% from high | |
| 63Notable | Chuck Ence CAO and COO buy | $299k 136,000 shares | +51% | +896% from low-26% from high | |
| 57Moderate | Paul Edward Kelly Chief Operating Officer buy | $198k 90,000 shares | +22% | +896% from low-26% from high | |
| 76Notable | Maged Shenouda Chief Financial Officer buy | $1.1M 500,000 shares | +173% | +896% from low-26% from high | |
| 74Notable | Sergio Traversa Chief Executive Officer buy | $600k 272,500 shares | +27% | +896% from low-26% from high | |
| 51Moderate | Sergio Traversa Chief Executive Officer buy | $178k 265,976 shares | +36% | +162% from low-82% from high | |
| 58Moderate | Chuck Ence CA and CO buy | $103k 228,961 shares | +588% | +83% from low-87% from high | |
| 62Notable | Paul Edward Kelly Chief Operating Officer buy | $86k 200,000 shares | +94% | +83% from low-87% from high | |
| 69Notable | Sergio Traversa Chief Executive Officer buy | $175k 350,000 shares | +91% | +83% from low-87% from high | |
| 65Notable | Maged Shenouda Chief Financial Officer buy | $97k 200,000 shares | +226% | +83% from low-87% from high |
Transactions
Every row filed, 36 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +100,000 | $4.18 | $418k | 1,400,000 | 32 d ago |
| Sep 9, 2026 | Maged Shenouda Chief Financial Officer | POpen-market purchase Common Stock | +120,200 | $4.20 | $505k | 920,200 | 32 d ago |
| Sep 10, 2026 | Maged Shenouda Chief Financial Officer | POpen-market purchase Common Stock | +79,800 | $4.25 | $339k | 1,000,000 | 32 d ago |
| Sep 10, 2026 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +100,000 | $4.10 | $410k | 1,500,000 | 32 d ago |
| Dec 15, 2025 | Maged Shenouda Chief Financial Officer | POpen-market purchase Common Stock | +11,665 | $4.12 | $48k | 800,000 | Dec 16, 2025 |
| Dec 15, 2025 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +27,500 | $4.12 | $113k | 1,300,000 | Dec 16, 2025 |
| Dec 12, 2025 | Charles J Casamento director | AGrant or award Stock Appreciation Rightsderivative | +164,000 | $0.00 | $0 | 164,000 | Dec 16, 2025 |
| Dec 12, 2025 | Chuck Ence CA and CO | AGrant or award Stock Appreciation Rightsderivative | +828,000 | $0.00 | $0 | 828,000 | Dec 16, 2025 |
| Dec 12, 2025 | Fabiana Fedeli director | AGrant or award Stock Appreciation Rightsderivative | +164,000 | $0.00 | $0 | 164,000 | Dec 16, 2025 |
| Dec 12, 2025 | John Glasspool director | AGrant or award Stock Appreciation Rightsderivative | +164,000 | $0.00 | $0 | 164,000 | Dec 16, 2025 |
| Dec 12, 2025 | Paul Edward Kelly COO | AGrant or award Stock Appreciation Rightsderivative | +828,000 | $0.00 | $0 | 828,000 | Dec 16, 2025 |
| Dec 12, 2025 | Maged Shenouda Chief Financial Officer | AGrant or award Stock Appreciation Rightsderivative | +828,000 | $0.00 | $0 | 828,000 | Dec 16, 2025 |
| Dec 12, 2025 | Sergio Traversa Chief Executive Officer | AGrant or award Stock Appreciation Rightsderivative | +1,198,000 | $0.00 | $0 | 1,198,000 | Dec 16, 2025 |
| Nov 5, 2025 | Chuck Ence CAO and COO | POpen-market purchase Common Stock | +136,000 | $2.20 | $299k | 403,931 | Nov 6, 2025 |
| Nov 5, 2025 | Paul Edward Kelly Chief Operating Officer | POpen-market purchase Common Stock | +90,000 | $2.20 | $198k | 502,295 | Nov 6, 2025 |
| Nov 5, 2025 | Maged Shenouda Chief Financial Officer | POpen-market purchase Common Stock | +500,000 | $2.20 | $1.1M | 788,335 | Nov 6, 2025 |
| Nov 5, 2025 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +272,500 | $2.20 | $600k | 1,272,500 | Nov 6, 2025 |
| Aug 26, 2025 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +80,545 | $0.62 | $50k | 814,569 | Aug 28, 2025 |
| Aug 27, 2025 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +129,455 | $0.67 | $87k | 944,024 | Aug 28, 2025 |
| Aug 28, 2025 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +55,976 | $0.74 | $41k | 1,000,000 | Aug 28, 2025 |
| Jun 26, 2025 | Charles J Casamento director | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 30, 2025 |
| Jun 26, 2025 | Chuck Ence CA and CO | AGrant or award Stock Option (right to buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jun 30, 2025 |
| Jun 26, 2025 | Fabiana Fedeli director | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 30, 2025 |
| Jun 26, 2025 | John Glasspool director | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 30, 2025 |
| Jun 26, 2025 | Paul Edward Kelly Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jun 30, 2025 |
| Jun 26, 2025 | Sergio Traversa Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +800,000 | $0.00 | $0 | 800,000 | Jun 30, 2025 |
| Jun 26, 2025 | Maged Shenouda Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Jun 30, 2025 |
| May 16, 2025 | Maged Shenouda Chief Financial Officer | POpen-market purchase Common Stock | +50,000 | $0.44 | $22k | 138,335 | May 20, 2025 |
| May 16, 2025 | Chuck Ence CA and CO | POpen-market purchase Common Stock | +228,961 | $0.45 | $103k | 267,931 | May 20, 2025 |
| May 16, 2025 | Paul Edward Kelly Chief Operating Officer | POpen-market purchase Common Stock | +200,000 | $0.43 | $86k | 412,295 | May 20, 2025 |
| May 16, 2025 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +172,314 | $0.45 | $77k | 556,338 | May 20, 2025 |
| May 19, 2025 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +30,000 | $0.50 | $15k | 586,338 | May 20, 2025 |
| May 19, 2025 | Maged Shenouda Chief Financial Officer | POpen-market purchase Common Stock | +90,000 | $0.49 | $44k | 228,335 | May 20, 2025 |
| May 20, 2025 | Sergio Traversa Chief Executive Officer | POpen-market purchase Common Stock | +147,686 | $0.56 | $82k | 734,024 | May 20, 2025 |
| May 20, 2025 | Maged Shenouda Chief Financial Officer | POpen-market purchase Common Stock | +60,000 | $0.52 | $31k | 288,335 | May 20, 2025 |
| Oct 22, 2024 | Charles J Casamento director | GGift Common Stock | -13,000 | $0.00 | $0 | 0 | Oct 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Charles J Casamentodirector
- Chuck EnceCA and CO
- Fabiana Fedelidirector
- John Glasspooldirector
- Paul Edward KellyCOO
- Maged ShenoudaChief Financial Officer
- Sergio TraversaChief Executive Officer
Questions about RLMD
Answered from the filings on this page, as of the latest one.
Are insiders buying RLMD?
As of Sep 11, 2026, SEC Form 4 filings show 2 open-market buys worth $1.7M by 2 insiders and 0 open-market sells worth $0 by 0 insiders at RELMADA THERAPEUTICS, INC. in the last 90 days, net +$1.7M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade RLMD on the open market?
Sergio Traversa (Chief Executive Officer) bought $828k of RLMD on Sep 9, 2026 and filed the Form 4 on Sep 11, 2026. InsiderTell scored 59 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at RELMADA THERAPEUTICS, INC.?
7 people have filed a Form 4 at RELMADA THERAPEUTICS, INC., among them Charles J Casamento (director), Chuck Ence (CA and CO), Fabiana Fedeli (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.